A pet drug efficacy test and a field trial for the evaluation of pet drugs conducted by Taizhou Bioally Technology Co Ltd – located in the Taizhou Medical High-tech Zone in Taizhou city, in East China's Jiangsu province – recently got the green light.
They met the requirements of the Good Clinical Practice or the GCP for veterinary medicine clinical trials, approved by the Animal Husbandry and Veterinary Bureau of the Ministry of Agriculture and Rural Affairs.
Currently, Bioally is the only company in China's pet medicine industry that holds dual GCP qualifications for both biological products and drugs.
The company is engaged in the research and development, production, and sales of innovative pet drugs, as well as third-party health testing services for pets.
In order to accelerate the commercialization of new products, the company invested over 200 million yuan ($27.52 million) to build the world's first fully functional pet health research and production plant. It has a floor space of 24,000 square meters and has been erected in accordance with European Union standards.
Having started operations in the first half of 2023, the plant aims to be the world's most comprehensive research and development and production center in the field of pet pharmaceuticals and health management.
An exterior view of the premises of Taizhou Bioally Technology Co Ltd. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]